- Home
- BCTX vs SNSE Comparison
BCTX vs SNSE Comparison
Compare BCTX & SNSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCTX
- SNSE
- Stock Information
- Founded
- BCTX 2014
- SNSE 2005
- Country
- BCTX Canada
- SNSE United States
- Employees
- BCTX N/A
- SNSE N/A
- Industry
- BCTX Biotechnology: Pharmaceutical Preparations
- SNSE Biotechnology: Pharmaceutical Preparations
- Sector
- BCTX Health Care
- SNSE Health Care
- Exchange
- BCTX Nasdaq
- SNSE Nasdaq
- Market Cap
- BCTX 16.1M
- SNSE 9.3M
- IPO Year
- BCTX N/A
- SNSE 2021
- Fundamental
- Price
- BCTX $3.18
- SNSE $0.38
- Analyst Decision
- BCTX Strong Buy
- SNSE Strong Buy
- Analyst Count
- BCTX 1
- SNSE 4
- Target Price
- BCTX $32.00
- SNSE $4.25
- AVG Volume (30 Days)
- BCTX 3.7M
- SNSE 158.0K
- Earning Date
- BCTX 06-13-2025
- SNSE 05-06-2025
- Dividend Yield
- BCTX N/A
- SNSE N/A
- EPS Growth
- BCTX N/A
- SNSE N/A
- EPS
- BCTX N/A
- SNSE N/A
- Revenue
- BCTX N/A
- SNSE N/A
- Revenue This Year
- BCTX N/A
- SNSE N/A
- Revenue Next Year
- BCTX N/A
- SNSE N/A
- P/E Ratio
- BCTX N/A
- SNSE N/A
- Revenue Growth
- BCTX N/A
- SNSE N/A
- 52 Week Low
- BCTX $0.35
- SNSE $0.25
- 52 Week High
- BCTX $9.82
- SNSE $1.94
- Technical
- Relative Strength Index (RSI)
- BCTX 37.13
- SNSE 46.57
- Support Level
- BCTX $4.04
- SNSE $0.36
- Resistance Level
- BCTX $9.82
- SNSE $0.44
- Average True Range (ATR)
- BCTX 0.75
- SNSE 0.03
- MACD
- BCTX -0.22
- SNSE 0.00
- Stochastic Oscillator
- BCTX 1.34
- SNSE 42.75
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).